Results 221 to 230 of about 148,411 (300)
Objective This study aimed to investigate the mechanisms of immune dysregulation in a pediatric patient with monogenic lupus driven by IKZF1 haploinsufficiency. Methods Peripheral immune cells from a patient with IKZF1 haploinsufficiency, patients with lupus with no currently known genetic mutations, and healthy controls were analyzed using single‐cell
Qi Zheng +6 more
wiley +1 more source
Objective The unknown pathophysiology and the lack of specific features for systemic juvenile idiopathic arthritis and adult‐onset Still disease (collectively known as Still disease; SD) delay diagnosis and appropriate treatment. The goal of this study was to identify features and mechanisms that distinguish SD from other systemic autoinflammatory ...
Yvonne M. Mueller +16 more
wiley +1 more source
Editorial: Advances in perinatal stem cells research and applications. [PDF]
Elkhenany H, Wu Q, Lotfy A.
europepmc +1 more source
Objective Here we investigate the status of the adiponectin–PEPITEM pathway in early, treatment naive rheumatoid arthritis (RA) and psoriatic arthritis (PsA) and the therapeutic efficacy of PEPITEM administration in preclinical models. Methods Peripheral blood was isolated from patients with clinical suspect arthralgia and suspected inflammatory ...
Mussarat Wahid +34 more
wiley +1 more source
Antitumor-Directed Fractionation of <i>Lophocereus marginatus</i> Extracts Against Murine L5178Y-R Lymphoma Cells. [PDF]
Torres-Hernández ÁD +9 more
europepmc +1 more source
GENOME WIDE DNA METHYLATION PROFILING IS PREDICTIVE OF OUTCOME IN JUVENILE MYELOMONOCYTIC LEUKEMIA [PDF]
Costello, J +8 more
core +1 more source
Objective Rituximab, a CD20+ B cell depletion therapy, is frequently used to treat systemic lupus erythematosus (SLE). However, variability in patient response highlights the need for a deeper understanding of the underlying immune cell dynamics of B cell depletion and repopulation.
Haerin Jang +9 more
wiley +1 more source
Objective Regeneration and expansion of Treg by low‐dose interleukin‐2 (IL‐2) therapy is considered a potential treatment strategy for a wide range of autoimmune diseases. To provide a pathophysiologically‐based rationale for low‐dose IL‐2 therapy, we investigated whether reversible defects in the Treg–IL‐2 axis emerge in inflammatory myopathies ...
Justus Ohmes +10 more
wiley +1 more source
Pharmacological Profile of Adenosine A<sub>2A</sub> Receptors as Biomarkers of Ischemia/Reperfusion Process During Coronary Artery Bypass Grafting. [PDF]
Gariboldi V +13 more
europepmc +1 more source

